Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SporeVax Influenza
- Development stage
- Preclinical
- Lead developer
- SporeGen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
SporeVax Influenza is a preclinical-stage, spore-based nasal mucosal vaccine developed by SporeGen (Spobiotic Research Center) for the prevention of influenza. The vaccine utilizes *Bacillus subtilis* spores as a delivery platform to present influenza antigens to the nasal mucosa, aiming to induce both systemic and local mucosal immunity. This approach is designed to provide a needle-free, stable, and potentially more effective alternative to traditional injectable vaccines by targeting the primary site of viral entry and leveraging the natural adjuvant properties of bacterial spores.
- Brand names
- SporeVax Influenza
- Other names
- SporeVax - Influenza
02
Targets
MYD88 (Myeloid differentiation primary response protein MyD88)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on SporeVax Influenza.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SporeVax Influenza.